Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.

Home > Health Conditions > Parkinson's > Dostinex (cabergoline)

Dostinex (cabergoline)

Related Topics:

• Agilect (rasagiline) / Apokyn® (apomorphine) / deprenyl / Dostinex (cabergoline) / L-dopa / Mirapex® (pramipexole) / Neupro (rotigotine) / Permax (pergolide) / Requip® (Ropinirole HCl) / Seroquel® (quetiapine) / Trivastal (piribedil)

News & Research:

• Parkinson's Drugs: Heart Damage Link? - WebMD, 1/3/07
• Choosing the Right Dopamine Agonist for Patients With Parkinson's Disease - Medscape, 9/6/02
• Long-Term Cabergoline Practical In Elderly With Parkinson’s Disease - Doctor's Guide, 7/30/01
• Cabergoline Delays Motor Complications More Effectively Than Levodopa In Parkinson’s Patients - Doctor's Guide, 6/20/01
• Dopamine Agonists Safe, Effective for Long-term Treatment of Restless Legs Syndrome - Doctor's Guide, 6/8/01
• Cabergoline May Be Effective In Reducing Symptoms Of Restless Legs Syndrome - Doctor's Guide, 10/25/00
• Cabergoline Shows Significant Advantages Over Pergolide In Parkinson's - Doctor's Guide, 3/8/00
• Cabergline Improves Nocturnal Parkinson’s Symptoms - Doctor's Guide, 9/10/99
• Dostinex Launched for Pituitary Gland Disorders - Doctor's Guide, 3/18/97
• Dostinex to Treat Hyperprolactinemia Receives FDA Clearance - Doctor's Guide, 12/26/96

Abstracts:

• Cabergoline monotherapy in the long-term treatment of Cushing's disease - Eur J Endocrinol. 2010 Aug 11 - "Within 3-6 months, complete response was achieved in 11 patients (36.6%) and partial response in 4 (13.3%). After longer term therapy, 9 patients (30%) remain with a complete response after a mean of 37 months (range from 12-60 months) with a mean dose of 2.1 mg/wk of cabergoline. Two patients escaped after 2 and 5 years of complete response, but one transiently renormalized UFC after an increase in cabergoline dosage. No long-term response was maintained in 4 initial partial responders. Conclusions: Cabergoline monotherapy can provide an effective long-term medical therapy for selected patients with CD, but requires close follow-up for dose adjustments"

Related Searches:

• Doctor's Guide search of cabergoline
• Doctor's Guide (2) search of Dostinex or cabergoline
• DrugStore.com price of Dostinex
• Life Extension Foundation search
• Medline search of cabergoline
• Medscape search of Dostinex or cabergoline
• Nutrition Science News search
• RxList search of cabergoline
• WebMD search of cabergoline

70701